Meeting
2020 ASCO Virtual Scientific Program
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
Authors
Erika Paige Hamilton
Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
Erika Paige Hamilton , Mafalda Oliveira , Udai Banerji , Cristina Hernando , Javier Garcia-Corbacho , Anne Armstrong , Eva Ciruelos , Manish R. Patel , Jason Incorvati , Chris Twelves , Tim Brier , Danielle Carroll , Steven Fox , Teresa Klinowska , Justin P O Lindemann , Richard Mather , Rhiannon Maudsley , Sam McGuinness , Andy Sykes , Richard Baird
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03616587
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1024)
DOI
10.1200/JCO.2020.38.15_suppl.1024
Abstract #
1024
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Mafalda Oliveira
Poster
2016 ASCO Annual Meeting
A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.
First Author: Elisabeth De Vries
Poster
2023 ASCO Annual Meeting
Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.
First Author: Mafalda Oliveira
Poster
2021 ASCO Annual Meeting
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
First Author: Seock-Ah Im